TXG: Margin operasi 10x Genomics, Inc.

Simbol resmi perusahaan 10xgenomics.com (TXG)

Stable plant utilization and robotics upgrades guarantee the uninterrupted production of cell analysis systems for 10x Genomics, Inc. (TXG). The operating margin trend captures this process, where the -11.50 metric determines this level. Dominance in spatial biology and patent protection provide 10x Genomics, Inc. (TXG) with pricing power, while reagent supplies to oncology and neurobiology centers effectively diversify the company's business risks.

TXG - Rentabilitas kegiatan operasi 10x Genomics Inc ing rentang 04.07.2022 - 19.11.2026

Rincian analitis perusahaan 10x Genomics, Inc. (TXG)

Analisis kabeh metrik perusahaan:10x Genomics, Inc., TXG
Produk merek 10x

10x Genomics, Inc. (TXG) leadership in spatial biology requires colossal investments in high-tech platforms. The operating margin reflects the efficiency of these activities by comparing operating profit to revenue before financial expenses and taxes. This ratio measures the business's ability to generate profit from its core cycle. Analyzing the marginal income from core operations allows for the identification of trend sustainability. Ignoring risks when interpreting this chart leads to losses.

Perusahaan pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|NTLA (Intellia Therapeutics, Inc.) - Rasio bathi operasi|Rentabilitas operasi Stoke Corp (STOK)|Rentabilitas kegiatan operasi BioLife|Margin operasi WVE (Wave Life Sciences Ltd)|MAZE: Rentabilitas dodolan miturut bathi operasi|Sionna Therapeutics, Inc. - Margin operasi|Tingkat bathi operasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Margin dodolan operasi|QURE - Rentabilitas kegiatan operasi|MGTX (MeiraGTx Corp) - Margin operasi|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi